Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial

Abstract

The significant antitumor activity combined with a mild toxicity profile seen in this study argue that GemCap chemotherapy may benefit patients with advanced biliary cancer. This regimen warrants further evaluation in a randomized study with survival and quality of life end points.